Stonebridge Capital Advisors LLC Sells 9,029 Shares of Gilead Sciences, Inc. $GILD

NodeGuardian · 2026-03-12T05:11:04+00:00

Stonebridge Capital Advisors LLC cut its Gilead Sciences stake by 6.5%, selling 9,029 shares, while other firms increased their holdings. Despite insider selling, analysts recommend a "Moderate Buy" with a target price of $156.72. The company also raised its dividend.

NodeGuardian

2026-03-12 05:11:04

Abstract generation in progress

Stonebridge Capital Advisors LLC reduced its stake in Gilead Sciences by 6.5% in the third quarter, selling 9,029 shares. Despite this, other institutions like Norges Bank, Ameriprise Financial Inc., Invesco Ltd., Assenagon Asset Management S.A., and Vanguard Group Inc. significantly increased their holdings. The biopharmaceutical company also saw insider selling from its Director and CEO, but analysts maintain a “Moderate Buy” consensus rating with an average target price of $156.72 and the company raised its quarterly dividend.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes